RxDoctor Payments Data

Shawna Hickman, NP

Family · Glendale, AZNPI 1609111426

Payments from drug & device makers

$7,125in general payments, 2019–2025

Across 416 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Amgen$913
  • Impulse Dynamics (USA) Inc.$551
  • Angiodynamics, Inc.$532
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$505
  • Tactile Systems Technology Inc$484
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$6,96798%
  • Education$1582%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,125 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$8,222
Medicare patients
49
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$97,767
Repatha SureclickEvolocumab36$30,392
XareltoRivaroxaban18$21,951
EntrestoSacubitril/Valsartan19$16,254
FarxigaDapagliflozin Propanediol20$14,137
BrilintaTicagrelor13$6,203
Atorvastatin Calcium116$1,358
Metoprolol Succinate107$1,091
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$923
Carvedilol84$915
Losartan Potassium109$860
ClopidogrelClopidogrel Bisulfate48$724
Amlodipine Besylate74$662
Nitroglycerin75$651
Nifedipine ErNifedipine23$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$83$97,767116 claims
AstraZenecaFarxiga, Brilinta$195$20,34033 claims
NovartisEntresto$2,000$16,25419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →